BTIG Rates Intuitive Surgical (ISRG) Buy, $454 Price Target
Key Points
- BTIG reiterated its Buy rating on Intuitive Surgical, Inc. (ISRG) on October 21, 2026, leaving its price target steady at $454.0.
- BTIG's $454 price target implies 3.65% upside from Intuitive Surgical, Inc.'s ($ISRG) current $438.02 share price.
- The medical device maker recently traded near $438.02, sitting above its 50-day moving average.
- Wall Street maintains a general buy consensus on the stock, with 30 analysts covering the company.
Get Intuitive Surgical text alerts
We text you when insiders, Congress, analysts or big funds move on $ISRG.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Intuitive Surgical, Inc. alert may contain errors. Disclosures
On October 21, 2026, research firm BTIG kept its Buy rating on Intuitive Surgical, Inc. (NasdaqGS: ISRG) and left its price target unchanged at $454.0. According to the firm's research note, the analyst kept the target steady at $454.0, matching the previous target of $454.0 from an earlier update. BTIG previously adjusted its target for the company to $454.0 on October 12, down from $469.0 on September 8.
ISRG
Intuitive Surgical, Inc.
BTIG vs. the S&P 500
Hypothetical returns from BTIG's disclosed trades, not real profit or advice. How we model this.
BTIG's Call on Intuitive Surgical, Inc.
In its October 21 update, BTIG reaffirmed its positive stance on the medical instruments maker without altering the target price. The firm's coverage sits alongside other recent updates from Wall Street. Earlier, on October 7, Barclays initiated coverage on the stock with an Overweight rating and a $485.0 price target. On the same day as BTIG's latest note, Baird maintained its Outperform rating while raising its price target to $550.0 from $513.0. Across the broader analyst community, 30 analysts share opinions on the stock, resulting in a buy consensus recommendation and a mean price target of $478.53.
Intuitive Surgical, Inc. Stock Up 2.7%
The shares recently traded at $438.02, up about 11.5% from their 50-day moving average of $392.76 and down slightly from the 200-day moving average of $438.97. On the trading day prior to the rating update, October 20, 2026, the stock closed at $438.0. The company carries a market capitalization of roughly $153.03 billion and a price-to-earnings ratio of 48.95 based on trailing results.
$ISRG price target
Intuitive Surgical, Inc. daily closes and this analyst's $454 target. Not advice.
Recent Earnings
For the trailing twelve months, the company generated $11.03 billion in revenue and reported earnings of $8.85 per share. Profitability metrics show a net profit margin of 28.4% and a return on equity of 17.4%. Year-over-year revenue growth stood at 18.5%.
Dividend
The company does not pay a dividend, maintaining a payout ratio of 0.0%.
Insider Buying and Selling at Intuitive Surgical, Inc.
Company insiders executed several transactions ahead of the analyst update. Officer Mark Preston Brosius sold 154 shares on August 21 for $59,439, followed by sales of 69 shares on September 9 for $24,671 and 48 shares on September 11 for $17,141. Additionally, officer Fredrik Widman sold 1,089 shares at $374.44 per share on September 15 for a total value of $407,765.
About Intuitive Surgical, Inc.
Based in Sunnyvale, California, Intuitive Surgical, Inc. designs, builds, and sells robotic systems and instruments that help doctors perform minimally invasive surgical procedures. Its technology aims to improve patient access and clinical outcomes in hospitals around the world. The company employs 17,021 people and is led by CEO David J. Rosa.
Bottom Line
BTIG's decision to keep its price target at $454.0 reflects steady expectations for the robotic surgery pioneer. Investors will watch for upcoming financial reports and further analyst updates to track how the medical device maker's growth aligns with Wall Street expectations.
Related Filing Alerts
Source: BTIG's rating change on $ISRG (Oct 21, 2026). Written by software, not financial advice. How we make alerts